Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....

SHR EE G AN ESH BI O - T E C H (I ND I A) L I M I TED CIN: L70101WB1982PLC121196 Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR, KAMDHENU BUILDING, KOLKATA -700016 Email: shreeganeshbiotechindialtd@gmail.com Website: www.shreeganeshbiotech.shop Date: 04.08.2026 To, To, To, Listing Department, The Secretary, Head - Listing BSE Limited, . The Calcutta Stock Exchange Ltd, Metropolitan Stock P J Tower, Dalal Street 7, Lyons Range, Exchange of India Limited Mumbai-400001 Kolkata - 700001 Vibgyor Towers, 4th floor, Plot Noe 62, Opp. Trident Hotel Bandra Kurla Complex, Bandra (E) Mumbai - 400098 Scrip Code: 539470 Scrip Code: 29221 Scrip Code-SHREEGANES Subject: Outcome of Board Meeting held on 4th August 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Tuesday 4th August,2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2026. The board meeting commented at 03:50 PM and concluded at 04:10 PM Please take the above intimation in your records. Thanking You, Yours Faithfully, FOR, SHREE GANESH BIO-TECH (INDIA)LIMITED AMAN PATEL WHOLETIME DIRECTOR DIN NO.: 08483544 Shree Ganesh Biotech (India) Ltd CIN:- L70101WB1982PLC121196 Regd. Office: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016 Email:- shreeganeshbiotechindialtd@gmail.com (Rs. In lacs) Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2026 Quarter Ended Year Ended Sl no. Particulars 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 (Refer Notes Below) (Unaudited) (Audited) (Unaudited) (Audited) INCOME (a) Gross Revenue from sale of products 142.99 212.13 138.36 497.05 (b) Other Operating Revenue - - - - 1 Revenue from Operations 142.99 212.13 138.36 497.05 2 Other Income 32.01 27.59 41.53 147.22 3 Total Income 175.00 239.72 179.89 644.27 EXPENSES (a) Cost of materials consumed 186.67 215.76 111.97 505.57 (b) Purchases of Stock-in-Trade - (c) Changes in inventories of finished goods, work-in-progress, - - - - and stock-in-trade (d) Employee benefit expense 5.85 4.35 1.43 16.48 (e) Finance Costs - - - - (f) Depreciation and amortization expense - 0.05 - 0.05 (g) Other expenses 39.81 34.48 33.79 70.75 4 Total Expenses 232.32 254.65 147.19 592.86 5 Profit / (Loss) from operations before exceptional items (57.32) ( 14.93) 32.70 51.41 Tax (1-2) 6 Exceptional Items - - - - 7 Profit / (Loss) before Tax (5 ± 6) (57.32) ( 14.93) 32.70 51.41 8 Tax Expense - - - 13.65 9 Net Profit / (Loss) after Tax (7 - 8) (57.32) ( 14.93) 32.70 37.76 10 Other Comprehensive Income (net of tax ) - - - - (i) Items that will not be reclassified to profit or loss - - - - A (ii) Income tax relating to items that will not be reclassified to - - - - profit or loss (i) Items that will be reclassified to profit or loss - - - - B (ii) Income tax relating to items that will be reclassified to - - - - profit or loss Total Comprehensive Income for the period (9 ± 10) (57.32) ( 14.93) 32.70 37.76 12 Paid-up equity share capital (Face Value of Rs.1/- each) 3,986.24 3,986.24 3,986.24 3,986.24 13 Other Equity - - - 2 ,377.10 14 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic (0.01) ( 0.00) 0.01 0.01 (b) Diluted (0.01) ( 0.00) 0.01 0.01 Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 04, 2026. The Statutory Auditors have carried out a limited review of the above financial result. 2 Company has only one segment and hence no separate segment result has been given. 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 4 Provison for Taxation if any will be made at year end. 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Shree Ganesh Biotech (India) Ltd Aman Patel Place : Kolkata Wholetime Director Date : 04th August, 2026 DIN: 08483544 BIPIN & Co. CA. TEJAS PUROHIT F.C.A.. DISA, M. Com. 98257 68699 CA. DHARIT K. SHAH FCA., Ll.B., B. Com. 94273 411~ CA. AIIIT D. SHAH F.CA., D.T.P., B. Com. 9426313900 CItARTEREd ACCOUNTANTS CA. SURESH SISODIA FCA., A.C.S., Ll.B. 98251 56037 ~ ...g llA' .. "_ l:.eS:' eene U9711_ Umited Review Report on unaudited standalone financial results of Shree Ganesh Biotech (India) Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India lUsting Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Shree Ganesh Biotech (India) Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Shree Ganesh Biotech (India) Umited ("the Company") for the quarter ended 30 June 2026 (lithe Statement"), being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('listing Regulations'), 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants.of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statements are free of material misstatement. review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard of Auditing and consequently does not enable us to obtain assurance that we, would become aware of all significant matters that might be identified in audit. AccordinglYI we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other recognized accounting practices generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. FOR, BIPIN & CO. CHARTERED ACCOUNTANTS CAAM~""'LJI' ~ PLACE: VAD DARA DATE: 04/08/ 026 UDIN: 26126337UCMZSS6345 Head Office : 302/301, Centre Point, R. C. Dull Road, Alkapuri, Vadodara-390007. Ph. : 0265-2338665, 2323577 E-mail: bipin.smdt@gmail.oo"ffi/bipin.co@gmail.com/amiCd_shah@rediffmail.com {